Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow lsa Template on Twitter
Research Article
Transparent Process
Open Access

Functional inhibition of acid sphingomyelinase disrupts infection by intracellular bacterial pathogens

View ORCID ProfileChelsea L Cockburn, Ryan S Green, Sheela R Damle, Rebecca K Martin, Naomi N Ghahrai, Punsiri M Colonne, Marissa S Fullerton, Daniel H Conrad, Charles E Chalfant, Daniel E Voth, View ORCID ProfileElizabeth A Rucks, Stacey D Gilk, View ORCID ProfileJason A Carlyon  Correspondence email
Chelsea L Cockburn
1Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, School of Medicine, Richmond, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Chelsea L Cockburn
Ryan S Green
1Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, School of Medicine, Richmond, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheela R Damle
1Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, School of Medicine, Richmond, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca K Martin
1Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, School of Medicine, Richmond, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naomi N Ghahrai
1Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, School of Medicine, Richmond, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Punsiri M Colonne
2Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marissa S Fullerton
2Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel H Conrad
1Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, School of Medicine, Richmond, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles E Chalfant
3Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel E Voth
2Department of Microbiology and Immunology, University of Arkansas for Medical Sciences, Little Rock, AR, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth A Rucks
4Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elizabeth A Rucks
Stacey D Gilk
5Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason A Carlyon
1Department of Microbiology and Immunology, Virginia Commonwealth University Medical Center, School of Medicine, Richmond, VA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jason A Carlyon
  • For correspondence: jason.carlyon@vcuhealth.org
Published 22 March 2019. DOI: 10.26508/lsa.201800292
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. FIASMAs inhibit A. phagocytophilum infection at a post bacterial invasion step through specific targeting of host cell ASM.

    (A–E, I, J) FIASMA treatment reduces the A. phagocytophilum DNA load in host cells. HL-60 cells (A, B, I, J), RF/6A cells (C), or human peripheral blood neutrophils (D) were treated with 10 μM (unless otherwise noted) desipramine (A, B), amitriptyline (I), nortriptyline (J), or DMSO vehicle control followed by incubation with A. phagocytophilum organisms. Total DNA isolated at the indicated time points was analyzed by qPCR. Relative levels of the A. phagocytophilum 16S rRNA (aph16s) gene were normalized to the relative levels of β-actin using the 2−ΔΔCT method. (E) Desipramine was added to A. phagocytophilum–infected cells beginning at 24 h followed by qPCR analysis. (F) Desipramine has no effect on A. phagocytophilum binding to host cells. RF/6A cells were exposed to desipramine or DMSO followed by incubation with A. phagocytophilum. At 1, 2, and 4 h, the cells were fixed, immunolabeled with antibody against the A. phagocytophilum surface protein, P44, and examined by immunofluorescence microscopy to determine the percentages of cells having bound A. phagocytophilum organisms. (G) Desipramine treatment of A. phagocytophilum does not alter infection of host cells. Host cell–free A. phagocytophilum bacteria were exposed to desipramine or DMSO followed by incubation with untreated HL-60 cells. At 24 h, the bacterial load was determined using qPCR. (H) The inhibitory effect of desipramine on A. phagocytophilum infection is due to its action on ASM, not acid ceramidase. HL-60 cells were treated with CA-074 Me or not followed by treatment with desipramine or vehicle control. The cells were then infected with A. phagocytophilum. At 24 and 48 h, the bacterial load was measured using qPCR. Error bars indicate SD. t test was used to test for a significant difference among pairs. One-way ANOVA with Tukey's post hoc test was used to test for a significant difference among groups. Statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001) values are indicated. ns, not significant. Data shown in (A) are representative of three experiments conducted in triplicate with similar results. Data in (B, D, F–J) are representative of two experiments conducted in triplicate with similar results. Data in (C) are representative of five experiments conducted in triplicate with similar results. Data in (E) are representative of seven experiments conducted in triplicate with similar results.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2. Functional inhibition of ASM halts ApV maturation and expansion.

    (A, B, D, E) Desipramine was added to RF/6A cells before infection with A. phagocytophilum and treatment was either maintained throughout the time course (A, B, D) or removed at 20 h (B, E). (C, F) Desipramine was added to A. phagocytophilum–infected RF/6A cells beginning at 20 h (C, F). DMSO served as vehicle control. At 20, 24, 28, and 32 h, the cells were fixed and examined by confocal microscopy for ApV maturation (A–C) and expansion (D–F). (A–C) Desipramine reversibly inhibits APH0032 expression and localization to the ApV. A. phagocytophilum–infected RF/6A cells were screened with antibodies targeting vimentin and APH0032 to demarcate and assess maturation of the ApV, respectively. DAPI was used to stain host cell nuclei and bacterial DNA. (A) Representative confocal micrographs of desipramine or DMSO-treated cells at the indicated postinfection time points. (B, C) Percentages of APH0032-positive ApVs determined for 100 cells for each of three biological replicates per condition. (D–F) Desipramine reversibly inhibits ApV expansion. The mean ApV pixel area was determined for 50 ApVs per time point per condition. Error bars indicate SD. t test was used to test for a significant difference among pairs. Statistically significant (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001) values are indicated. ns, not significant. Data shown are representative of three experiments conducted in triplicate with similar results. Scale bar = 10 μm.

  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. Desipramine does not alter vimentin, Beclin-1, or TGN46 recruitment to the ApV and promotes cholesterol accumulation in lysosomes.

    (A–D) Localization of vimentin, Beclin-1, and TGN46 to the ApV are unaffected by desipramine. RF/6A cells were treated with desipramine or DMSO followed by infection with A. phagocytophilum. At 24 h, the cells were fixed; immunolabeled with antibodies targeting A. phagocytophilum P44 and vimentin (A and B), vimentin and Beclin-1 (C), or vimentin and TGN46 (D); stained with DAPI; and examined by confocal microscopy. (A) Representative confocal micrographs of desipramine- or DMSO-treated cells demonstrating vimentin recruitment to the periphery of ApVs containing P44-immunolabeled intravacuolar A. phagocytophilum organisms. (B) The percentage of ApVs from the experiment presented in panel A with which vimentin associated was 100% whether DMSO or desipramine was present. t test was used to test for a significant difference among pairs. ns, not significant. (C, D) Representative confocal micrographs of desipramine- or DMSO-treated cells depicting Beclin-1 (C) and TGN46 (D) recruitment to vimentin-positive ApVs. (E) Desipramine promotes cholesterol accumulation in lysosomes. Live cell imaging was performed following the addition of LysoTracker Red and BODIPY cholesterol (chol) to RF/6A cells that had been treated with desipramine or DMSO. Data shown in (A–D) are representative of three experiments conducted in triplicate with similar results. Data shown in (E) are representative of two experiments conducted in triplicate with similar results. Scale bars = 10 μm.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3. Desipramine inhibits A. phagocytophilum conversion to the infectious form.

    (A) Desipramine inhibits aph1235 transcription. Desipramine-treated HL-60 cells were infected with A. phagocytophilum. Total RNA isolated at 24, 28, and 32 h was subjected to qRT-PCR. The 2−ΔΔCT method was used to determine the relative aph1235 expression level normalized to that of A. phagocytophilum 16S rRNA. (B, C) Desipramine inhibits APH1235 protein expression. Desipramine-treated RF/6A cells were infected with A. phagocytophilum. At 24, 28, and 32 h, the cells were fixed, immunolabeled with APH1235 and vimentin antibodies, stained with DAPI, and visualized using confocal microscopy. (B) Representative confocal micrographs. Scale bar = 10 μM. (C) Percentage of APH1235-positive ApVs determined by counting 100 cells for each of triplicate samples per time point. (D) Desipramine inhibits A. phagocytophilum–infectious progeny production. RF/6A cells were treated with desipramine or DMSO followed by infection with A. phagocytophilum. At 48 h, the cells were mechanically disrupted followed by isolation and subsequent incubation of host cell–free bacteria with naïve untreated cells. At 24 h, the recipient cells were fixed and examined by immunofluorescence microscopy to determine the percentage that had become infected. Error bars indicate SD. t test was used to test for a significant difference among pairs. Statistically significant (**P < 0.01; ***P < 0.001; ****P < 0.0001) values are indicated. Data shown in (A–C) are representative of three experiments conducted in triplicate that yielded similar results. Data shown in (D) are representative of two experiments conducted in triplicate with similar results.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4. Desipramine alters NPC1-mediated cholesterol trafficking to the ApV.

    Desipramine treatment inhibits NPC1 localization to the ApV. Desipramine- or DMSO-treated RF/6A cells were infected A. phagocytophilum. (A–E) At 24 h, the cells were either fixed, immunolabeled with vimentin and NPC1 antibodies, stained with DAPI, and examined by confocal microscopy (A, B); or incubated with BODIPY ceramide (cer) or BODIPY cholesterol (chol), stained with Hoechst 33342, and visualized by live cell imaging (C–E). (A) Representative confocal micrographs of infected cells immunolabeled for vimentin and NPC1. Regions that are demarcated by hatched-line boxes are magnified in the inset panels. (B) Percentage of vimentin-positive ApVs to which NPC1 immunosignal localizes in DMSO- and desipramine-treated cells determined by counting 100 cells for each of triplicate samples per condition. (C) Representative live cell images of infected cells incubated with BODIPY-cer and BODIPY-chol. (D, E) Percentages of ApVs to which BODIPY-cer–positive (D) or BODIPY-chol–positive (E) vesicles localize. Error bars indicate SD. t test was used to test for a significant difference among pairs. Statistically significant (****P < 0.001) values are indicated. ns, not significant. Data shown are representative of three experiments conducted in triplicate that yielded similar results. Scale bar = 10 μm.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5. ASM is essential for A. phagocytophilum to productively infect mice.

    (A) A. phagocytophilum fails to productively infect ASM−/− mice. (A) ASMase−/− mice or WT mice were infected with A. phagocytophilum DC organisms. Peripheral blood drawn on days 4, 8, 12, 16, 21, and 28 d postinfection was analyzed by qPCR. Relative levels of the A. phagocytophilum 16S rRNA gene were normalized to those of β-actin using the 2−ΔΔCT method. (B) Desipramine reduces the A. phagocytophilum DNA load in the peripheral blood when administered to infected mice. A. phagocytophilum–infected WT mice were administered desipramine or PBS on days 7 through 12 postinfection, and the bacterial DNA load in the peripheral blood was determined using qPCR. Error bars indicate SD. t test was used to test for a significant difference among pairs. Statistically significant (**P < 0.01) values are indicated. Data shown in (A) are representative of eight experiments each of which were conducted with 5–7 mice per group. Data shown in (B) are representative of three experiments each of which were conducted with 5–7 mice per group.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6. Desipramine-induced cholesterol accumulation in the C. burnetii vacuole is bactericidal.

    (A, B) mCherry-C. burnetii (Cb)–infected THP-1 macrophage-like cells (A) or mCherry-C. burnetii grown in axenic medium (B) were treated with desipramine or not treated with. The bacterial load was measured as relative fluorescent units. (C–E) C. burnetii was added to HeLa cells (C, E) or MH-S cells (D) that had been pretreated with desipramine or DMSO, or C. burnetii–infected cells were treated at the indicated days postinfection (E). Bacterial load was measured using a CFU assay. (F) CCV area was determined for desipramine and DMSO-treated C. burnetii–infected HeLa cells. (G) HeLa cells that had been treated with desipramine and infected with mCherry-C. burnetii were labeled with filipin and CD63 antibody. Error bars indicate SD. t test was used to test for a significant difference among pairs. Statistically significant (**P < 0.01; ***P < 0.001; ****P < 0.0001) values are indicated. ns, not significant. Data in panels A and B are representative of three experiments conducted in triplicate with similar results. Data in panels C through F are the means ± SD of three independent experiments. Scale bar = 50 μm.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7. C. trachomatis and C. pneumoniae exhibit reduced FIASMA sensitivity.

    (A–D) Desipramine or DMSO-treated HeLa cells infected with C. trachomatis (Ctr; A, B) or C. pneumoniae (Cpn; C, D) were either lysed to recover infectious progeny that were incubated with naïve HeLa cells to determine inclusion-forming units (A, C) or were fixed and assessed by immunofluorescence microscopy to determine inclusion area (B, D). (E–J) Desipramine-treated or control cells were infected with Ctr (E, G, I) or Cpn (F, H, J). The cells were either incubated with filipin (E, F) or screened with antibodies specific for LBPA (G, H) or CERT (I, J) together with antisera against C. trachomatis (E, G, I) or C. pneumoniae (F, H, J). DAPI or DRAQ5 was used to stain DNA. Regions that are demarcated by hatched-line boxes are magnified in the inset panels. Error bars indicate SD. t test was used to test for a significant difference among pairs. Statistically significant (*P < 0.05; ***P < 0.001) values are indicated. Data shown are representative of three experiments conducted in triplicate with similar results. Scale bar = 10 μm.

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. Desipramine treatment does not inhibit Golgi recruitment to chlamydial inclusions.

    (A–D) Desipramine- or DMSO-treated HeLa cells were infected with C. trachomatis (Ctr; A, C) or C. pneumoniae (Cpn; B, D). The cells were fixed and labeled with either syntaxin 6 (A, B) or VAMP4 antibody (C, D), antisera against Ctr or Cpn, and stained with DAPI. Data shown are representative of three experiments conducted in triplicate with similar results. Scale bar = 10 μm.

PreviousNext
Back to top
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Functional inhibition of acid sphingomyelinase disrupts infection by intracellular bacterial pathogens
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
FIASMAs inhibit intracellular bacterial infections
Chelsea L Cockburn, Ryan S Green, Sheela R Damle, Rebecca K Martin, Naomi N Ghahrai, Punsiri M Colonne, Marissa S Fullerton, Daniel H Conrad, Charles E Chalfant, Daniel E Voth, Elizabeth A Rucks, Stacey D Gilk, Jason A Carlyon
Life Science Alliance Mar 2019, 2 (2) e201800292; DOI: 10.26508/lsa.201800292

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
FIASMAs inhibit intracellular bacterial infections
Chelsea L Cockburn, Ryan S Green, Sheela R Damle, Rebecca K Martin, Naomi N Ghahrai, Punsiri M Colonne, Marissa S Fullerton, Daniel H Conrad, Charles E Chalfant, Daniel E Voth, Elizabeth A Rucks, Stacey D Gilk, Jason A Carlyon
Life Science Alliance Mar 2019, 2 (2) e201800292; DOI: 10.26508/lsa.201800292
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
Issue Cover

In this Issue

Volume 2, No. 2
April 2019
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Immunology
  • Medical Research
  • Microbiology, Virology & Host Pathogen Interaction

Related Articles

  • No related articles found.

Cited By...

  • Immunization against Anaplasma phagocytophilum Adhesin Binding Domains Confers Protection against Infection in the Mouse Model
  • Binding of Host Cell Surface Protein Disulfide Isomerase by Anaplasma phagocytophilum Asp14 Enables Pathogen Infection
  • Google Scholar

More in this TOC Section

  • Crosstalk between HIF and AHR
  • The human phagocytosis molecular machinery
  • iTAP/Frmd8 modulates inflammation and tumor growth
Show more Research Article

Similar Articles

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2023 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.